A drug-drug interaction study of Lanabecestat (LY3314814) in healthy participants

Study identifier:15997

ClinicalTrials.gov identifier:NCT02568397

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Effect of LY3314814 on the Pharmacokinetics of Dabigatran in Healthy Subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Lanabecestat, Dabigatran etexilate

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 31 Oct 2015

Primary Completion Date: 31 Jan 2016

Study Completion Date: 31 Jan 2016

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Oct 2019 by AstraZeneca

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: Dabigatran Etexilate Single dose of dabigatran etexilate administered orally.	Drug: Dabigatran etexilate Administered orally
Experimental: Lanabecestat and Dabigatran Etexilate Single dose of lanabecestat administered orally once daily on Days 3 to 21. Single doses of dabigatran etexilate administered orally on Days 16 and 20 during the lanabecestat dosing.	Drug: Lanabecestat Administered orally Other Name: LY3314814 Other Name: AZD3293 Drug: Dabigatran etexilate Administered orally

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Information Center

1-877-240-9479

[email protected]

Investigators

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)